Skip to main content

KV Pharmaceutical, Gedeon Richter announce licensing agreement


BUDAPEST, Hungary An American drug maker has signed a licensing agreement with a Hungarian pharmaceutical company.

KV Pharmaceutical Co. announced that it had entered into an agreement with Budapest, Hungary-based Gedeon Richter and its American subsidiary for licensing rights to KV technologies and products in the women’s health category.

Under the agreement, Gedeon Richter will have the right to manufacture and distribute certain proprietary technologies and products from KV in the European Union and other areas where it does business, while KV will receive undisclosed milestones and royalties for products that the two companies develop. KV will retain U.S. rights.

“KV Pharmaceutical and Gedeon Richter have for many years enjoyed an excellent relationship and business collaboration, and we are very pleased to extend it in this fashion,” KV Pharmaceutical Co. interim CEO David Van Vliet stated. “We believe this agreement allows both Richter and KV to offer additional enhanced products to more completely serve physicians and their patients.”

This ad will auto-close in 10 seconds